Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway

Poly (ADP-ribose) polymerase 1 inhibitors (PARPi) are used to treat recurrent ovarian cancer (OC) patients due to greater survival benefits and minimal side effects, especially in those patients with complete or partial response to platinum-based chemotherapy. However, acquired resistance of platinu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahar, Entaz, Kim, Ji-Ye, Kim, Dong-Chul, Kim, Hyun-Soo, Yoon, Hyonok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070209/
https://www.ncbi.nlm.nih.gov/pubmed/33920140
http://dx.doi.org/10.3390/ijms22083916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070209/
https://www.ncbi.nlm.nih.gov/pubmed/33920140
http://dx.doi.org/10.3390/ijms22083916

Ejemplares similares